Limosilactobacillus reuteri, still widely known by its former name Lactobacillus reuteri, is a species of lactic acid bacterium that naturally inhabits the gastrointestinal tracts of many vertebrates, including humans. It is one of the most heavily researched probiotic organisms in the world, with clinical trials linking specific strains to benefits ranging from reduced infant colic crying to improved cholesterol levels. What makes L. reuteri unusual among probiotics is the depth of its evolutionary relationship with its hosts and the diversity of mechanisms through which it influences human health, from producing its own antimicrobial compounds to modulating the immune system and even affecting hormonal signaling in the brain.
Where L. Reuteri Comes From
L. reuteri is not a newcomer hitching a ride in the human gut. Phylogenomic analyses show that distinct lineages of this bacterium have been co-evolving with vertebrate hosts for an extraordinarily long time. The oldest branches of the L. reuteri family tree are dominated by strains from rodents and birds, while lineages found in humans, pigs, and herbivores emerged more recently. Strains from rodent lineages efficiently colonize the mouse forestomach in laboratory experiments, while strains from unrelated hosts do not, a strong sign that these bacteria have become genetically tailored to their particular host species over millennia.
Experiments using germ-free mice have confirmed that rodent-adapted L. reuteri strains outperform strains from other animals when colonizing the rodent gut, and that knocking out rodent-specific genes in those strains impairs their ability to thrive there.
For humans, the picture is more complicated. L. reuteri was once commonly found in the human gut, but modern Western populations harbor it far less frequently than people in traditional or rural societies. Researchers suspect that changes in diet, widespread antibiotic use, and other aspects of industrialized life have reduced our exposure. This decline is part of the reason supplementation has attracted so much research interest: if the bacterium co-evolved with us but is now disappearing, restoring it might recover lost health benefits.
How L. Reuteri Works in the Body
L. reuteri employs several mechanisms that distinguish it from many other probiotic species. The most distinctive is its ability to produce reuterin, an antimicrobial compound generated from glycerol. Reuterin is broadly active against a range of intestinal pathogens, with most tested gut bacteria showing sensitivity at relatively low concentrations, while beneficial lactobacilli tend to be more resistant.
Beyond reuterin, L. reuteri produces organic acids and other metabolites that help keep pathogenic microbes in check and reshape the local microbial community.
On the immune side, L. reuteri has a well-documented ability to promote the expansion of regulatory T cells, a type of immune cell that acts as a brake on overactive immune responses. In mouse studies, oral L. reuteri treatment increased the number of these regulatory cells in the spleen and enhanced their ability to suppress inflammatory immune activity.
L. reuteri also reinforces the physical barrier of the gut lining. Lab studies using intestinal cell models show that pre-treating cells with L. reuteri strains protects the tight junction proteins that hold the gut wall together when the cells are exposed to harmful bacteria or inflammatory molecules like bacterial toxins. In newborn piglets given L. reuteri daily for two weeks, the abundance of key barrier proteins increased significantly compared with untreated animals.
Infant Colic
The benefit with the strongest clinical backing is the reduction of crying time in infants with colic. Multiple randomized, double-blind, placebo-controlled trials have tested the strain L. reuteri DSM 17938 in colicky babies, and the results have been consistently positive. In one trial, infants given L. reuteri were about three times more likely to achieve at least a 50% reduction in crying time compared to those given a placebo by day 21 of treatment.
A separate clinic-based study found that average daily crying time dropped from roughly four hours at the start of the study to under one hour by the end, with 85% of infants meeting the threshold for a meaningful clinical response.
The effect appears most robust in breastfed infants, and the mechanism likely involves a combination of L. reuteri’s influence on gut motility and its modulation of the infant gut microbiome. One study mapping gut contractions found that DSM 17938 increased the frequency of contractions in both the small intestine and colon while also affecting the speed at which those contractions moved, which could help explain why it eases the digestive distress associated with colic.
Digestive Health in Adults
The evidence in adults is more mixed but still promising for certain conditions. In a randomized trial of adults with chronic functional constipation, those taking L. reuteri had an average increase of about 2.6 bowel movements per week after four weeks, compared with an increase of about one per week in the placebo group. Stool consistency did not change significantly between groups, suggesting the bacterium’s effect was primarily on motility rather than stool composition.
For Helicobacter pylori, the bacterium responsible for most stomach ulcers, L. reuteri has been studied both as a standalone treatment and as an add-on to standard antibiotic therapy. In trials testing L. reuteri alone against standard triple therapy, eradication rates were similar between the two approaches, though neither achieved the high cure rates clinicians ideally want. Where L. reuteri seems to add clearer value is in reducing the side effects of antibiotic-based eradication regimens. A study on sequential therapy found that adding L. reuteri supplementation reduced both the frequency and intensity of antibiotic-associated side effects, which matters because side effects are a leading reason patients abandon H. pylori treatment before it works.
Cholesterol
One of the more striking metabolic findings involves L. reuteri NCIMB 30242, a strain with particularly active bile salt hydrolase enzymes. In a randomized controlled trial of adults with elevated cholesterol, this strain reduced LDL cholesterol by about 12% and total cholesterol by about 9% compared with placebo. The mechanism appears to involve the bacterium’s ability to break down bile salts in the intestine, which reduces the reabsorption of cholesterol-related compounds. The trial measured drops in plant sterols in the blood (markers of cholesterol absorption), confirming that reduced absorption was the pathway at work rather than, say, increased cholesterol breakdown in the liver.
These are meaningful numbers in the context of cholesterol management. For comparison, dietary interventions like increasing soluble fiber intake typically yield LDL reductions in the range of 5-10%. Whether this particular strain’s effects hold up in larger trials and translate to reduced heart disease events is still unknown, but the initial data is encouraging enough that it is sometimes marketed specifically for cardiovascular support.
Blood Sugar and Insulin
The relationship between L. reuteri and blood sugar regulation is more nuanced and less settled. In healthy, glucose-tolerant volunteers, daily L. reuteri SD5865 boosted the release of GLP-1 (a gut hormone that signals the pancreas to produce insulin) by about 76% and increased insulin secretion by roughly half compared with placebo. That sounds dramatic, but the same study found no change in overall insulin sensitivity, body weight, or fat distribution, suggesting the hormonal boost did not translate into broader metabolic improvements in people who were already healthy.
In people with type 2 diabetes, results have been inconsistent. One trial using DSM 17938 for 12 weeks found no significant effect on HbA1c (a measure of long-term blood sugar control), liver fat, or body composition, though a post hoc analysis hinted that people who entered the trial with more diverse gut microbiomes responded better. A separate trial using a different strain, L. reuteri ADR-1, did find a modest but statistically significant reduction in HbA1c over six months, and the benefit persisted for three months after participants stopped taking it. The heat-killed version of a related strain, ADR-3, showed no such benefit, reinforcing that strain choice and viability matter.
The honest read of the evidence is that L. reuteri can influence the hormonal machinery of blood sugar regulation, but whether that translates into clinically meaningful improvements for people with diabetes depends heavily on which strain is used, how long it is taken, and likely on the individual’s existing gut microbiome.
Bone Density
An intriguing line of research connects L. reuteri to bone health. In ovariectomized mice, a model that mimics postmenopausal bone loss, L. reuteri treatment completely prevented the loss of trabecular bone volume in both the femur and vertebrae, preserving bone at levels similar to those of intact control animals.
This led to a human trial in older women with low bone mineral density, where L. reuteri ATCC PTA 6475 reduced the loss of total volumetric bone density by about half compared with placebo over 12 months. However, a larger and longer follow-up trial in early postmenopausal women tested both a high and low dose of the same strain over two years and found no significant differences in bone density at the tibia, lumbar spine, or hip compared with placebo at either dose.
The discrepancy may reflect differences in the study populations. The first trial enrolled women who already had low bone density, meaning they were losing bone at a faster clip and had more room for a probiotic to make a detectable difference. The second enrolled women earlier in menopause with less severe bone loss, and it is possible the effect simply was not large enough to stand out. For now, the bone-density benefit remains plausible but unproven in humans, and it would be premature to take L. reuteri as a substitute for established osteoporosis treatments.
Skin Conditions and Eczema
L. reuteri has been tested in children with atopic dermatitis (eczema) with modestly encouraging results. In one trial, 56% of children improved during active treatment with L. reuteri compared with 15% on placebo, and the extent of affected skin shrank significantly. The benefit was most pronounced in children whose eczema was driven by allergic sensitization, those with positive skin-prick tests and elevated IgE antibodies, suggesting the bacterium’s immune-modulating effects matter most when the immune system is clearly overreacting.
A separate study found that L. reuteri supplementation in children with atopic dermatitis shifted the balance of inflammatory signaling molecules in their exhaled breath, increasing interferon-gamma and decreasing interleukin-4, a pattern consistent with dampening the type of immune response that drives allergic disease. Again, this shift only occurred in atopic children, not in those with non-allergic dermatitis.
For prevention, the picture is less clear. One trial giving L. reuteri to infants from birth found no overall reduction in the rate of eczema development, but during the second year of life, children in the treatment group had significantly less IgE-associated eczema (8% versus 20%), pointing to a delayed and allergy-specific protective effect rather than a blanket reduction in skin disease.
Vaginal Health
L. reuteri RC-14, typically combined with L. rhamnosus GR-1, has been studied for bacterial vaginosis (BV), a condition characterized by a disrupted vaginal microbiome. In a randomized trial of women with BV, those who received a single dose of the antibiotic tinidazole plus daily probiotic capsules containing both strains had an 88% cure rate after four weeks, compared with 50% in the antibiotic-plus-placebo group. More women in the probiotic group also had their vaginal microbiota graded as “normal” by standard scoring criteria.
A separate observational study reported that 92% of patients achieved complete lactobacilli recolonization during treatment. These are among the stronger clinical results for any probiotic in vaginal health, though it is worth noting that the combination always uses both strains together, so isolating L. reuteri RC-14’s individual contribution is difficult.
The Oxytocin Connection
One of the more surprising research threads involves L. reuteri and the hormone oxytocin. In mouse models, feeding L. reuteri increased oxytocin-producing cells in the hypothalamus, boosted systemic oxytocin levels, and lowered the stress hormone corticosterone. These hormonal shifts were accompanied by measurably faster skin wound healing.
The pathway appears to run through the vagus nerve, the major communication highway between the gut and the brain. When researchers transferred regulatory T cells from L. reuteri-treated mice into immune-deficient animals that had never been exposed to the bacterium, those recipient animals gained improved wound-healing capacity as well, suggesting that the immune cells themselves carry the benefit once they are primed.
A small pilot study extended this to humans, reporting that oral L. reuteri improved wound repair capacity in human subjects, though this work remains very early-stage and the practical implications are speculative. The broader significance is that it illustrates how a single gut bacterium can influence biology far from the intestine, acting through a gut-microbe-brain-immune axis.
Why Strain Identity Matters
One of the most important practical points about L. reuteri is that not all strains do the same thing. The species encompasses considerable genetic diversity, with recent taxonomic work identifying at least eight distinct lineages and proposing several new subspecies based on genomic analysis. Strains isolated from rodents, birds, pigs, and primates carry different gene repertoires shaped by their host environments.
For consumers, this means a supplement labeled “L. reuteri” could contain any number of different strains with different capabilities. DSM 17938 is the strain behind most infant colic research. NCIMB 30242 is the cholesterol strain. ATCC PTA 6475 is the bone and oxytocin strain. RC-14 is the vaginal health strain, nearly always paired with L. rhamnosus GR-1. ADR-1 is the strain showing some promise for blood sugar in people with type 2 diabetes. These are not interchangeable.
A product using a generic or poorly characterized L. reuteri strain cannot be assumed to deliver the benefits demonstrated for a specific well-studied strain. This is a common pitfall in the probiotic market, where marketing language often implies that all members of a species share the same properties. Looking for the specific strain designation on the label, not just the species name, is the single most useful thing you can do when choosing a product.
Safety and Practical Considerations
L. reuteri has a long track record of safe use in clinical trials across age groups, from newborns to elderly adults. The most commonly studied strains have been granted Generally Recognized as Safe (GRAS) status. Side effects in trials are typically mild and gastrointestinal, things like temporary gas or bloating, and occur at rates similar to placebo groups.
Dosing varies by strain and condition. Infant colic studies generally use around 100 million colony-forming units (CFU) per day, while adult metabolic and cholesterol studies have used doses in the billions. Taking more is not necessarily better; the trial of L. reuteri for bone health in early postmenopausal women found no dose-response relationship between the low and high doses tested.
Timing and food interactions are not well standardized. Some products recommend taking L. reuteri with a meal on the logic that food buffers stomach acid and improves survival to the intestine, but study protocols have varied widely on this point. If you are immunocompromised or critically ill, probiotics of any kind warrant a conversation with your doctor, since live bacteria carry theoretical risks in people whose immune defenses are severely weakened.
Shelf life and storage also matter. L. reuteri is a living organism, and products that have been improperly stored or are past their expiration date may contain far fewer viable bacteria than the label claims. Refrigerated products generally maintain potency better than shelf-stable ones, though some formulations are engineered for room-temperature stability.